Attard, G., Agarwal, N., Graff, J. N., Sandhu, S., Efstathiou, E., Özgüroğlu, M., Gomes, A. J. P. D. S., Vianna, K. C. M., Luo, H., Cheng, H. H., Kim, W., Varela, C. R., Schaeffer, D., Dibaj, S., Li, S., Shen, F., Mundle, S. D., Olmos, D., Chi, K. N., Rathkopf, D. (2025). Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.17_suppl.lba5006